posted
I'm posting last weeks PR. Again I say, this stock is highly undervalued! Check 2 week chart!
Grant Life Sciences Awarded Patent for Vital Components of Blood-Based Cervical Cancer Test Thursday September 22, 4:51 pm ET Patent Marks Major Company Milestone and Significant Step toward Product Commercialization
MURRAY, Utah--(BUSINESS WIRE)--Sept. 22, 2005--Grant Life Sciences (OTC Bulletin Board: GLIF - News) today announced that it was recently awarded a U. S. patent for essential components of its proprietary technology for diagnosing cervical cancer. ADVERTISEMENT
"The issuance of this patent represents a significant milestone for Grant Life Sciences in our drive toward an effective, commercial blood test for cervical cancer and its precursors," said Michael Ahlin, the company's vice president and founder. "Issuance is a validation of our original and ongoing work on cancer detection, and we can now progress more effectively and confidently toward further development and ultimate commercialization of our cervical cancer test."
The patent (Number 6,933,123) encompasses essential components of the company's proprietary technology: "Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers."
Ahlin explained that cervical cancer remains the second most common cancer among women worldwide. For over 50 years, the Pap smear has been the most widely used method for screening for cervical cancer, but it has proven consistently inadequate for detecting the disease in its early, most curable stages. As a result, each year about 500,000 women worldwide are diagnosed with invasive cervical cancer, and more than 300,000 women die of the disease.
According to Ahlin, the overwhelming cause of cervical cancer (over 99% of cases) is infection by the human papillomavirus (HPV). The newly issued patent encompasses novel amino acid sequences, or small proteins, isolated from particular genetic regions of HPV types 16 and 18, which are responsible for most cervical cancers. These novel proteins developed by Grant Life Sciences function as probes in a more rapid, sensitive, and specific test for detecting or diagnosing HPV-associated cellular abnormalities, precancerous lesions, and cancers.
"There remains an urgent need for a comparatively simple, inexpensive and sensitive blood test for the early detection of cervical cancer," Ahlin stated. "We at Grant Life Sciences are proud and excited that we have been moving progressively toward meeting that need."
Ahlin noted that Institutional Review Board-approved studies at multiple medical centers are underway in the move to perfect and finalize the cervical cancer test.
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious, or economic reasons. Further information is available at: www.grantlifesciences.com.
IP: Logged |
MURRAY, Utah, Oct 06, 2005 (BUSINESS WIRE) -- Grant Life Sciences (GLIF, Trade) announced today that it has appointed Hun-Chi Lin, Ph.D., as the Company's President, Chief Scientist and a Director, effective immediately. The Company also announced the resignation of Eric Wilkinson as co-CEO and as an Officer and a Director of Grant Life Sciences.
Since 2003, Dr. Hun-Chi Lin was a co-founder and President of XepMed, Inc., which develops medical devices used for separating blood components and treating infectious diseases. From 1999 to present, Dr. Lin was a co-founder and President of BioMedical Research Laboratories, Inc., which developed a Web-based healthcare partner-connectivity system to be used by individual health maintenance organizations, individuals, and in clinical trials. From 1996 to 1999, Dr. Lin was Director of Clinical Trials at Specialty Laboratories (SP, Trade), where he built and managed a clinical trials division that had the broadest esoteric-testing capabilities in the CRO (Contract Research Organization) industry.
"Dr. Lin is a highly effective executive who possesses a very strong scientific background in the clinical research and clinical laboratory services industries," said Stan Yakatan, Chairman of Grant Life Sciences. "No doubt, his education and experience will serve Grant Life Sciences well as the Company moves forward with clinically validating its rapid test for detecting cervical cancer.
"We are very grateful to Eric Wilkinson, who has helped us considerably during this recent transition period. When Eric accepted the co-CEO role upon my retirement from the CEO role, it was expected that he would continue moving our science forward until such time as we were able to identify the perfect candidate to assume the role of President and Chief Scientist," added Mr. Yakatan.
Dr. Lin earned his doctorate in microbiology at UCLA (University of California at Los Angeles). He is the author of 34 peer-reviewed publications and the inventor of three issued patents.
About Grant Life Sciences Inc.
Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.
-------------------- It is better to be thought a fool than to speak and remove all doubt.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
